This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Mepolizumab for hypereosinophilic syndrome – add-on therapy

< Back

Mepolizumab for hypereosinophilic syndrome – add-on therapy


Immunology and Allergy

January 2020

Mepolizumab is a medicinal product currently in development as an add-on for the treatment of hypereosinophilic syndrome (HES). HES is a rare group of inflammatory disorders characterised by an overproduction of eosinophils (a type of disease-fighting white blood cell). When eosinophils infiltrate certain tissues, they can cause inflammation and organ damage which, over time, can impact patients’ day-to-day ability to function. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected.
Mepolizumab is given by injection and works by blocking the activity of human interleukin-5 (IL-5), an immune protein that is responsible for the production and survival of eosinophils. By blocking the activity of IL-5, the production and survival of the eosinophils is reduced. Using mepolizumab in addition to the standard of care may improve outcomes and reduce symptoms in patients with HES.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts